

Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency

Submission date 30/09/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 30/09/2005	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 02/02/2017	Condition category Circulatory System	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Kevin Burnand

Contact details

Guy's and St Thomas' NHS Foundation Trust
General, Vascular and Colorectal Surgery Department
F01 North Wing
St Thomas' Hospital
Lambeth Palace Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 2570
Kevin.burnand@kcl.ac.uk

Additional identifiers

Protocol serial number

N0013146069

Study information

Scientific Title

Treatment with doxycycline to promote the healing of chronic venous ulcer and markers of chronic venous insufficiency: a randomised controlled trial

Study objectives

1. Is haemosiderin a reliable marker for venous insufficiency?
2. Does the inhibition of matrix metalloproteinase play any role in the healing of ulcer?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiovascular: Venous ulcers

Interventions

Patients will be randomised into either treatment or control group. Each group will be matched according to ulcer size. The treatment group will take two daily 100mg of doxycycline and the patients in the control group will take matched placebo tablets. A biopsy from the ulcer will be obtained before the start of the study and at 8 weeks. Sample will be used to determine the Matrix Metalloproteinase (MMPs) level.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Haemosiderin

Primary outcome(s)

Ulcer sizes, complete or incomplete healing

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/12/2007

Eligibility

Key inclusion criteria

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/09/2003

Date of final enrolment

01/12/2007

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Guy's and St Thomas' NHS Foundation Trust

London

United Kingdom

SE1 7EH

Sponsor information

Organisation

Department of Health

Funder(s)

Funder type

Government

Funder Name

Guy's and St. Thomas' NHS Foundation Trust (UK)

Funder Name

Own Account - NHS R&D Support Funding

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration